Standout Papers

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate ... 2016 2026 2019 2022 688
  1. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (2016)
    Matthew D. Hellmann, Naiyer A. Rizvi et al. The Lancet Oncology
  2. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer (2017)
    Puneeth Iyengar, Zabi Wardak et al. JAMA Oncology
  3. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Scott Gettinger, Naiyer A. Rizvi et al. Journal of Clinical Oncology
  4. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 21 from Science/Nature 68 standout
Sub-graph 1 of 21

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Why do patients with cancer die?
2024 Standout
1 intermediate paper

Works of David E. Gerber being referenced

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2016 Standout
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
2010

Author Peers

Author Last Decade Papers Cites
David E. Gerber 5231 4268 405 1769 284 9.2k
Bhumsuk Keam 5905 3935 526 2090 367 9.6k
Patricia Keegan 4830 3055 216 2001 140 9.0k
Sumithra J. Mandrekar 4171 3267 258 1730 208 8.9k
Taofeek K. Owonikoko 5683 3314 306 3698 321 10.3k
Joachim G.J.V. Aerts 4752 5317 185 1909 323 10.2k
Anthony Elias 5774 3463 408 2124 204 9.6k
Anna K. Nowak 4121 4956 735 1515 352 10.9k
Jeffrey Crawford 6647 2720 473 1369 199 10.0k
Stephen V. Liu 3994 2440 265 1666 332 6.6k
Rajeshwari Sridhara 4648 2785 338 2952 137 9.1k

All Works

Loading papers...

Rankless by CCL
2026